Annual Total Liabilities
$1.17 B
-$604.70 M-34.00%
31 December 2023
Summary:
Emergent BioSolutions annual total liabilities is currently $1.17 billion, with the most recent change of -$604.70 million (-34.00%) on 31 December 2023. During the last 3 years, it has fallen by -$262.30 million (-18.26%). EBS annual total liabilities is now -34.00% below its all-time high of $1.78 billion, reached on 31 December 2022.EBS Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$969.40 M
-$157.80 M-14.00%
30 September 2024
Summary:
Emergent BioSolutions quarterly total liabilities is currently $969.40 million, with the most recent change of -$157.80 million (-14.00%) on 30 September 2024. Over the past year, it has dropped by -$226.50 million (-18.94%). EBS quarterly total liabilities is now -45.50% below its all-time high of $1.78 billion, reached on 31 December 2022.EBS Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -34.0% | -18.9% |
| 3 y3 years | -18.3% | -27.9% |
| 5 y5 years | -3.7% | -25.4% |
EBS Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -34.0% | at low | -45.5% | at low |
| 5 y | 5 years | -34.0% | at low | -45.5% | at low |
| alltime | all time | -34.0% | +6199.4% | -45.5% | +2288.0% |
Emergent BioSolutions Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $969.40 M(-14.0%) |
| June 2024 | - | $1.13 B(-1.1%) |
| Mar 2024 | - | $1.14 B(-2.9%) |
| Dec 2023 | $1.17 B(-34.0%) | $1.17 B(-1.8%) |
| Sept 2023 | - | $1.20 B(-2.2%) |
| June 2023 | - | $1.22 B(-30.0%) |
| Mar 2023 | - | $1.75 B(-1.8%) |
| Dec 2022 | $1.78 B(+32.1%) | $1.78 B(+21.9%) |
| Sept 2022 | - | $1.46 B(+19.4%) |
| June 2022 | - | $1.22 B(+1.4%) |
| Mar 2022 | - | $1.21 B(-10.5%) |
| Dec 2021 | $1.35 B(-6.3%) | $1.35 B(+0.1%) |
| Sept 2021 | - | $1.34 B(-1.9%) |
| June 2021 | - | $1.37 B(-0.4%) |
| Mar 2021 | - | $1.38 B(-4.1%) |
| Dec 2020 | $1.44 B(+15.9%) | $1.44 B(+5.2%) |
| Sept 2020 | - | $1.36 B(+7.7%) |
| June 2020 | - | $1.27 B(+5.3%) |
| Mar 2020 | - | $1.20 B(-2.8%) |
| Dec 2019 | $1.24 B(+1.7%) | $1.24 B(-4.6%) |
| Sept 2019 | - | $1.30 B(-2.5%) |
| June 2019 | - | $1.33 B(+14.3%) |
| Mar 2019 | - | $1.17 B(-4.3%) |
| Dec 2018 | $1.22 B(+671.7%) | $1.22 B(+488.7%) |
| Sept 2018 | - | $206.97 M(+3.2%) |
| June 2018 | - | $200.54 M(+7.1%) |
| Mar 2018 | - | $187.19 M(+18.5%) |
| Dec 2017 | $157.90 M(-57.8%) | $157.90 M(-56.2%) |
| Sept 2017 | - | $360.49 M(+3.0%) |
| June 2017 | - | $349.88 M(+2.5%) |
| Mar 2017 | - | $341.22 M(-8.7%) |
| Dec 2016 | $373.91 M(-0.9%) | $373.91 M(-2.7%) |
| Sept 2016 | - | $384.40 M(+0.2%) |
| June 2016 | - | $383.79 M(+4.0%) |
| Mar 2016 | - | $368.92 M(-2.3%) |
| Dec 2015 | $377.47 M | $377.47 M(+1.7%) |
| Sept 2015 | - | $371.24 M(-2.6%) |
| June 2015 | - | $381.07 M(+0.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $379.97 M(-1.4%) |
| Dec 2014 | $385.49 M(+180.4%) | $385.49 M(+8.2%) |
| Sept 2014 | - | $356.15 M(+1.9%) |
| June 2014 | - | $349.48 M(+1.1%) |
| Mar 2014 | - | $345.76 M(+151.5%) |
| Dec 2013 | $137.47 M(+12.6%) | $137.47 M(+6.9%) |
| Sept 2013 | - | $128.61 M(+20.7%) |
| June 2013 | - | $106.53 M(+3.9%) |
| Mar 2013 | - | $102.58 M(-16.0%) |
| Dec 2012 | $122.10 M(-6.2%) | $122.10 M(+9.4%) |
| Sept 2012 | - | $111.61 M(+6.7%) |
| June 2012 | - | $104.62 M(+2.0%) |
| Mar 2012 | - | $102.59 M(-21.2%) |
| Dec 2011 | $130.14 M(+2.7%) | $130.14 M(+1.3%) |
| Sept 2011 | - | $128.46 M(+13.9%) |
| June 2011 | - | $112.75 M(+0.4%) |
| Mar 2011 | - | $112.35 M(-11.4%) |
| Dec 2010 | $126.76 M(+25.7%) | $126.76 M(+45.3%) |
| Sept 2010 | - | $87.24 M(+4.2%) |
| June 2010 | - | $83.70 M(-10.6%) |
| Mar 2010 | - | $93.67 M(-7.1%) |
| Dec 2009 | $100.87 M(+10.3%) | $100.87 M(+27.0%) |
| Sept 2009 | - | $79.42 M(-17.3%) |
| June 2009 | - | $95.98 M(+5.5%) |
| Mar 2009 | - | $91.00 M(-0.5%) |
| Dec 2008 | $91.44 M(-10.7%) | $91.44 M(-3.3%) |
| Sept 2008 | - | $94.57 M(-2.3%) |
| June 2008 | - | $96.80 M(+1.9%) |
| Mar 2008 | - | $95.04 M(-7.1%) |
| Dec 2007 | $102.35 M(+2.6%) | $102.35 M(+22.9%) |
| Sept 2007 | - | $83.26 M(+24.3%) |
| June 2007 | - | $66.98 M(+1.7%) |
| Mar 2007 | - | $65.87 M(-34.0%) |
| Dec 2006 | $99.78 M(+145.8%) | $99.78 M(+34.7%) |
| Sept 2006 | - | $74.07 M(+82.5%) |
| Dec 2005 | $40.59 M(-12.0%) | $40.59 M(-12.0%) |
| Dec 2004 | $46.11 M(+147.4%) | $46.11 M |
| Dec 2002 | $18.64 M(-67.7%) | - |
| Dec 2001 | $57.72 M | - |
FAQ
- What is Emergent BioSolutions annual total liabilities?
- What is the all time high annual total liabilities for Emergent BioSolutions?
- What is Emergent BioSolutions annual total liabilities year-on-year change?
- What is Emergent BioSolutions quarterly total liabilities?
- What is the all time high quarterly total liabilities for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly total liabilities year-on-year change?
What is Emergent BioSolutions annual total liabilities?
The current annual total liabilities of EBS is $1.17 B
What is the all time high annual total liabilities for Emergent BioSolutions?
Emergent BioSolutions all-time high annual total liabilities is $1.78 B
What is Emergent BioSolutions annual total liabilities year-on-year change?
Over the past year, EBS annual total liabilities has changed by -$604.70 M (-34.00%)
What is Emergent BioSolutions quarterly total liabilities?
The current quarterly total liabilities of EBS is $969.40 M
What is the all time high quarterly total liabilities for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly total liabilities is $1.78 B
What is Emergent BioSolutions quarterly total liabilities year-on-year change?
Over the past year, EBS quarterly total liabilities has changed by -$226.50 M (-18.94%)